Logo

ChondroGene Raises $500,000 in Private Placement

Sep 13, 2004

NEW YORK, Sept. 13 (GenomeWeb News) - ChondroGene of Toronto has raised $500,000 in a private placement in Canada, bringing the total of this financing round to $5.5 million, the company said today.

 

Last month, ChondroGene raised $5 million in a private placement in the US under the same terms, $.95 per common share.

 

The funding will provide the company with operating capital into 2006. ChondroGene, which develops disease-specific biomarkers, plans to advance its technology into areas outside of osteoarthritis, such as cancer and neurological disorders.

Breaking News
The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.